DOCSLIB.ORG

PERTH, WEDNESDAY, 29 AUGUST 2018 No. 127 SPECIAL PUBLISHED by AUTHORITY KEVIN J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PERTH, WEDNESDAY, 29 AUGUST 2018 No. 127 SPECIAL PUBLISHED by AUTHORITY KEVIN J !2018127GG! WESTERN 2995 AUSTRALIAN GOVERNMENT ISSN 1448-949X (print) ISSN 2204-4264 (online) PRINT POST APPROVED PP665002/00041 PERTH, WEDNESDAY, 29 AUGUST 2018 No. 127 SPECIAL PUBLISHED BY AUTHORITY KEVIN J. McRAE, GOVERNMENT PRINTER AT 12.00 NOON © STATE OF WESTERN AUSTRALIA Misuse of Drugs Act 1981 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 Made by the Governor in Executive Council. 1. Citation This order is the Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018. 2. Commencement This order comes into operation as follows — (a) clauses 1 and 2 — on the day on which this order is published in the Gazette; (a) the rest of the order — on the day after that day. 3. Act amended This order amends the Misuse of Drugs Act 1981. 4. Schedule III amended (1) At the beginning of Schedule III insert: Division 1 — General (2) In Schedule III: (a) delete item 17A and insert: 17A. BENZOYLINDOLES (plant material) 60.0 2996 GOVERNMENT GAZETTE, WA 29 August 2018 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 17B. BENZOYLINDOLES (in any form except plant material) 4.0 (b) delete item 25A and insert: 25A. 1-BUTYL-3-(1-NAPHTHOYL) INDOLE (JWH-073) (plant material) 60.0 25B. 1-BUTYL-3-(1-NAPHTHOYL) INDOLE (JWH-073) (in any form except plant material) 4.0 (c) delete item 34A and insert: 34A. 1-CYCLOHEXYLETHYL-3-(2- METHOXYPHENYLACETYL) INDOLE (RCS-8) 60.0 (plant material) 34AA. 1-CYCLOHEXYLETHYL-3-(2- METHOXYPHENYLACETYL) INDOLE (RCS-8) (in any form except plant material) 4.0 (d) delete item 34B and insert: 34B. CYCLOHEXYLPHENOLS (plant material) 60.0 34C. CYCLOHEXYLPHENOLS (in any form except plant material) 4.0 (e) delete item 38A and insert: 38A. DIBENZOPYRANS (plant material) 60.0 29 August 2018 GOVERNMENT GAZETTE, WA 2997 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 38B. DIBENZOPYRANS (in any form except plant material) 4.0 (f) delete item 46B and insert: 46B. 5-(1,1-DIMETHYLHEPTYL)-2-[(1R,3S)-3- HYDROXYCYCLOHEXYL]-PHENOL (CP 47,497) (plant material) 60.0 46BA. 5-(1,1-DIMETHYLHEPTYL)-2-[(1R,3S)-3- HYDROXYCYCLOHEXYL]-PHENOL (CP 47,497) (in any form except plant material) 4.0 (g) delete item 46C and insert: 46C. 5-(1,1-DIMETHYLOCTYL)-2-[(1R,3S)-3- HYDROXYCYCLOHEXYL]-PHENOL (CANNABICYCLOHEXANOL or CP 47,497 C8 HOMOLOGUE) (plant material) 60.0 46D. 5-(1,1-DIMETHYLOCTYL)-2-[(1R,3S)-3- HYDROXYCYCLOHEXYL]-PHENOL (CANNABICYCLOHEXANOL or CP 47,497 C8 HOMOLOGUE) (in any form except plant material) 4.0 (h) after item 48 insert: 48A. DIPHENIDINE 4.0 (i) delete item 58; 2998 GOVERNMENT GAZETTE, WA 29 August 2018 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 (j) delete item 59A and insert: 59A. 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL) INDOLE (AM-694) (plant material) 60.0 59AA. 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL) INDOLE (AM-694) (in any form except plant material) 4.0 59AB. 1-(5-FLUOROPENTYL)-N-(1-METHYL-1- PHENYLETHYL)-1H-INDAZOLE-3- CARBOXAMIDE (SGT-25) (plant material) 60.0 59AC. 1-(5-FLUOROPENTYL)-N-(1-METHYL-1- PHENYLETHYL)-1H-INDAZOLE-3- CARBOXAMIDE (SGT-25) (in any form except plant material) 4.0 (k) delete item 59B and insert: 59B. 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL) INDOLE (AM-2201) (plant material) 60.0 59C. 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL) INDOLE (AM-2201) (in any form except plant material) 4.0 (l) after item 59 insert: 59AAA. GAMMA HYDROXY BUTRATE (4-HYDROXYBUTANOIC ACID) 4.0 29 August 2018 GOVERNMENT GAZETTE, WA 2999 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 (m) delete item 63A and insert: 63A. 1-HEXYL-3-(1-NAPHTHOYL) INDOLE (JWH-019) (plant material) 60.0 63B. 1-HEXYL-3-(1-NAPHTHOYL) INDOLE (JWH-019) (in any form except plant material) 4.0 (n) delete item 66A and insert: 66A. 9-(HYDROXYMETHYL)-6,6-DIMETHYL-3-(2- METHYLOCTAN-2-YL)-6A,7,10,10A- TETRAHYDROBENZO[C] CHROMEN-1-OL (HU-210) (plant material) 60.0 66B. 9-(HYDROXYMETHYL)-6,6-DIMETHYL-3-(2- METHYLOCTAN-2-YL)-6A,7,10,10A- TETRAHYDROBENZO[C] CHROMEN-1-OL (HU-210) (in any form except plant material) 4.0 (o) after item 80A insert: 80AA. 2-METHOXYDIPHENIDINE (2-MXP or MXP) (plant material) 60.0 80AB. 2-METHOXYDIPHENIDINE (2-MXP or MXP) (in any form except plant material) 4.0 (p) delete item 80BA and insert: 80BA. 4-METHOXYPHENYL(1-BUTYL-1H-INDOL-3- YL)-METHANONE (RCS-4 (C4)) (plant material) 60.0 80BAA. 4-METHOXYPHENYL(1-BUTYL-1H-INDOL-3- YL)-METHANONE (RCS-4 (C4)) (in any form except plant material) 4.0 3000 GOVERNMENT GAZETTE, WA 29 August 2018 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 (q) delete item 80BB and insert: 80BB. 2-(4-METHOXYPHENYL)-1-(1-PENTYL- 1H-INDOL-3-YL)-ETHANONE (JWH-201) (plant material) 60.0 80BBA. 2-(4-METHOXYPHENYL)-1-(1-PENTYL- 1H-INDOL-3-YL)-ETHANONE (JWH-201) (in any form except plant material) 4.0 (r) delete item 80B and insert: 80B. 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL- 3-YL) ETHANONE (JWH-250) (plant material) 60.0 80CA. 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL- 3-YL) ETHANONE (JWH-250) (in any form except plant material) 4.0 (s) delete item 80C and insert: 80C. 2-(3-METHOXYPHENYL)-1-(1-PENTYLINDOL- 3-YL) ETHANONE (JWH-302) (plant material) 60.0 80D. 2-(3-METHOXYPHENYL)-1-(1-PENTYLINDOL- 3-YL) ETHANONE (JWH-302) (in any form except plant material) 4.0 (t) after item 80 insert: 81A. METHYL (S)-2-[1-(5-FLUOROPENTYL)-1H- INDAZOLE-3-CARBOXAMIDO]-3,3-DIMETHY LBUTANOATE (5F-ADB) (plant material) 60.0 29 August 2018 GOVERNMENT GAZETTE, WA 3001 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 81B. METHYL (S)-2-[1-(5-FLUOROPENTYL)-1H- INDAZOLE-3-CARBOXAMIDO]-3,3- DIMETHYLBUTANOATE (5F-ADB) (in any form except plant material) 4.0 81C. METHYL 2-(1-(5-FLUOROPENTYL)-1H- INDAZOLE-3-CARBOXAMIDO)-3- METHYLBUTANOATE (5F-AMB) (plant material) 60.0 81D. METHYL 2-(1-(5-FLUOROPENTYL)-1H- INDAZOLE-3-CARBOXAMIDO)-3- METHYLBUTANOATE (5F-AMB) (in any form except plant material) 4.0 (u) delete item 94A and insert: 94A. 1-[2-(4-MORPHOLINYL) ETHYL]-3-(1- NAPHTHOYL) INDOLE (JWH-200) (plant material) 60.0 94B. 1-[2-(4-MORPHOLINYL) ETHYL]-3-(1- NAPHTHOYL) INDOLE (JWH-200) (in any form except plant material) 4.0 (v) after item 94 insert: 94AA. N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2- YL)-1-(CYCLOHEXYLMETHYL)-1H- INDAZOLE-3-CARBOXAMIDE (MAB-CHMINACA or ADB-CHMINACA) (plant 60.0 material) 94AB. N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2- YL)-1-(CYCLOHEXYLMETHYL)-1H- INDAZOLE-3-CARBOXAMIDE (MAB-CHMINACA or ADB-CHMINACA) (in any form except plant material) 4.0 3002 GOVERNMENT GAZETTE, WA 29 August 2018 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 94AC. N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2- YL)-1-(5-FLUOROPENTYL)-1H-INDOLE-3- CARBOXAMIDE (5F-ADBICA) (plant material) 60.0 94AD. N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2- YL)-1-(5-FLUOROPENTYL)-1H-INDOLE-3- CARBOXAMIDE (5F-ADBICA) (in any form except plant material) 4.0 94AE. N-[1-(AMINOCARBONYL)-2,2- DIMETHYLPROPYL]-1-PENTYL-1H- INDAZOLE-3-CARBOXAMIDE (ADB-PINACA) (plant material) 60.0 94AF. N-[1-(AMINOCARBONYL)-2,2- DIMETHYLPROPYL]-1-PENTYL-1H- INDAZOLE-3-CARBOXAMIDE (ADB-PINACA) (in any form except plant material) 4.0 94AG. N-(1-[AMINOCARBONYL)-2- METHYLPROPYL]-1- (CYCLOHEXYLMETHYL)-1H-INDAZOLE-3- CARBOXAMIDE (AB-CHMINACA) (plant material) 60.0 94AH. N-(1-[AMINOCARBONYL)-2- METHYLPROPYL]-1- (CYCLOHEXYLMETHYL)-1H-INDAZOLE-3- CARBOXAMIDE (AB-CHMINACA) (in any form except plant material) 4.0 94AI. N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)- 1-(5-FLUOROPENTYL)-1H-INDOLE-3- CARBOXAMIDE (5F-ABICA) (plant material) 60.0 94AJ. N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)- 1-(5-FLUOROPENTYL)-1H-INDOLE-3- CARBOXAMIDE (5F-ABICA) (in any form except plant material) 4.0 29 August 2018 GOVERNMENT GAZETTE, WA 3003 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 94AK. N-[(1S)-1-(AMINOCARBONYL)-2- METHYLPROPYL]-1-(5-FLUOROPENTYL)-1H- INDAZOLE-3-CARBOXAMIDE (5F-AB-PINACA) (plant material) 60.0 94AL. N-[(1S)-1-(AMINOCARBONYL)-2- METHYLPROPYL]-1-(5-FLUOROPENTYL)-1H- INDAZOLE-3-CARBOXAMIDE (5F-AB-PINACA) (in any form except plant material) 4.0 (w) delete item 95A and insert: 95A. NAPHTHOYLINDOLES (plant material) 60.0 95AB. NAPHTHOYLINDOLES (in any form except plant material) 4.0 (x) delete item 95B and insert: 95B. NAPHTHYLMETHYLINDOLES (plant material) 60.0 95BA. NAPHTHYLMETHYLINDOLES (in any form except plant material) 4.0 (y) delete item 95C and insert: 95C. NAPHTHOYLPYRROLES (plant material) 60.0 95CA. NAPHTHOYLPYRROLES (in any form except plant material) 4.0 3004 GOVERNMENT GAZETTE, WA 29 August 2018 Misuse of Drugs (Amounts of Prohibited Drugs) Order 2018 cl. 4 (z) delete item 95D and insert: 95D. NAPHTHYLMETHYLINDENES (plant material) 60.0 95DA. NAPHTHYLMETHYLINDENES (in any form except plant material) 4.0 (aa) delete item 110AA and insert: 110AA. 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL) INDOLE (JWH-398) (plant material) 60.0 110AAA. 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL) INDOLE (JWH-398) (in any form except plant material) 4.0 (ab) delete item 110AB and insert: 110AB. 1-PENTYL-3-(2-CHLOROPHENYLACETYL) INDOLE (JWH-203) (plant material) 60.0 110ABA. 1-PENTYL-3-(2-CHLOROPHENYLACETYL) INDOLE (JWH-203) (in any form except plant material) 4.0 (ac) delete item 110AC and insert: 110AC. 1-PENTYL-3-(4-ETHYL-1-NAPHTHOYL) INDOLE (JWH-210) (plant material) 60.0 110ACA.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • 159 Misuse of Drugs (Controlled Drugs) Order 2001
    MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 BR 37/2001 MISUSE OF DRUGS ACT 1972 1972 : 159 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 The Minister of Health and Family Services, in exercise of the powers conferred on him by section 3(2) of the Misuse Of Drugs Act 1972, makes the following Order: Citation 1 This Order may be cited as the Misuse Of Drugs (Controlled Drugs) Order 2001. Amendment of Schedule 2 to Act No. 159 of 1972 2 Part I of Schedule 2 to the Misuse of Drugs Act 1972 is deleted and the new Part I set forth in the Schedule to this Order is substituted. Commencement 3 This Order commences on 1st August, 2001. SCHEDULE 2 (paragraph 2) PART I 1. The following substances and products, namely:- (a) ACETORPHINE ACETYLDIHYDROCODEINE ALFENTANIL ALLYLPRODINE ALPHACETYLMETHADOL 1989 Revision 1 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 ALPHAMEPRODINE ALPHAMETHADOL ALPHAPRODINE ALPRAZOLAM AMPHETAMINE ANILERIDINE ATAMESTANE BENZETHIDINE BENZPHETAMINE BENZYLMORPHINE (3-Benzylmorphine) BETACETYLMETHADOL BETAMEPRODINE BETAMETHADOL BETAPRODINE BEZITRAMIDE BOLANDIOL BOLASTERONE BOLAZINE BOLDENONE BOLENOL BOLMANTALATE BROMAZEPAM BUFOTENINE BUPRENORPHINE CALUUSTERONE CAMAZEPAM CANNABINOL DERIVATIVES CANNABINOL except where contained in Cannabis or Cannabis resin CANNABIS AND CANNABIS RESIN CARFENTANIL CATHINE CATHINONE CHLORDIAZEPOXIDE CHLORPHENTERMINE 4-CHLOROMETHANDIENONE CHORIONIC GONADOTROPHIN (HCG) and NON-HUMAN CHORIONIC GONADOTROPHIN CLENBUTEROL CLOBAZAM CLONAZEPAM CLONITAZENE CLORAZEPIC ACID CLOSTEBOL 2 1989 Revision MISUSE
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Pros and Cons Controversy on Molecular Imaging and Dynamic
    Open Access Archives of Biotechnology and Biomedicine Research Article Pros and Cons Controversy on Molecular Imaging and Dynamics of Double- ISSN Standard DNA/RNA of Human Preserving 2639-6777 Stem Cells-Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium-4 Nucleus (Alpha Particle) Using Synchrotron Radiation Alireza Heidari* Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA *Address for Correspondence: Dr. Alireza Abstract Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, In the current study, we have investigated pros and cons controversy on molecular imaging and dynamics USA, Email: of double-standard DNA/RNA of human preserving stem cells-binding Nano molecules with Androgens/ [email protected]; Anabolic Steroids (AAS) or Testosterone derivatives through tracking of Helium-4 nucleus (Alpha particle) using [email protected] synchrotron radiation. In this regard, the enzymatic oxidation of double-standard DNA/RNA of human preserving Submitted: 31 October 2017 stem cells-binding Nano molecules by haem peroxidases (or heme peroxidases) such as Horseradish Peroxidase Approved: 13 November 2017 (HPR), Chloroperoxidase (CPO), Lactoperoxidase (LPO) and Lignin Peroxidase (LiP) is an important process from Published: 15 November 2017 both the synthetic and mechanistic point of view. Copyright: 2017 Heidari A. This is an open access article distributed under the Creative
    [Show full text]